-+ 0.00%
-+ 0.00%
-+ 0.00%

argenx Moves Forward With First-In-Class MuSK Agonist ARGX-119 For CMS After Proof-of-Concept Achieved In Phase 1b Study

Benzinga·06/30/2025 07:55:32
Listen to the news
  • Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes
  • Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures
  • Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative discovery model